ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 604,01
1,28%
Dow Jones
42 123,97
0,00%
DAX
18 996,63
0,89%
Brent Oil
74,595
1,17%
Bitcoin
63 720,20
0,62%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Durect Corp (DRRX)

  7. Durect Corp (DRRX) Actualités

DRRX

Durect (DRRX)

Durect Corp
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:DRRX
DateHeureSourceTitreSymboleSociété
11/09/202418h53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DRRXDurect Corp
04/09/202422h30PR Newswire (US)DURECT Corporation to Present at the H.C. Wainwright Global Investment ConferenceNASDAQ:DRRXDurect Corp
26/08/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:DRRXDurect Corp
14/08/202423h01Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:DRRXDurect Corp
13/08/202422h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DRRXDurect Corp
12/08/202422h15Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:DRRXDurect Corp
12/08/202422h10Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:DRRXDurect Corp
12/08/202422h05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:DRRXDurect Corp
02/08/202422h30Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:DRRXDurect Corp
21/05/202414h00PR Newswire (US)DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated HepatitisNASDAQ:DRRXDurect Corp
14/05/202422h03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DRRXDurect Corp
13/05/202422h05PR Newswire (US)DURECT Corporation Reports First Quarter 2024 Financial Results and Business UpdateNASDAQ:DRRXDurect Corp
07/05/202422h30PR Newswire (US)DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business UpdateNASDAQ:DRRXDurect Corp
30/04/202413h00PR Newswire (US)DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated HepatitisNASDAQ:DRRXDurect Corp
27/03/202421h01PR Newswire (US)DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:DRRXDurect Corp
20/03/202421h30PR Newswire (US)DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business UpdateNASDAQ:DRRXDurect Corp
04/03/202413h00PR Newswire (US)DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and CanadaNASDAQ:DRRXDurect Corp
14/02/202422h16Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:DRRXDurect Corp
08/02/202400h48PR Newswire (US)DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:DRRXDurect Corp
13/11/202322h05PR Newswire (US)DURECT Corporation Reports Third Quarter 2023 Financial Results and Business UpdateNASDAQ:DRRXDurect Corp
09/11/202322h30PR Newswire (US)DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business UpdateNASDAQ:DRRXDurect Corp
07/11/202322h01PR Newswire (US)DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on MortalityNASDAQ:DRRXDurect Corp
07/09/202313h00PR Newswire (US)DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated HepatitisNASDAQ:DRRXDurect Corp
31/08/202322h30PR Newswire (US)DURECT Corporation Announces Presentations in Upcoming Investor ConferencesNASDAQ:DRRXDurect Corp
10/08/202322h21Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:DRRXDurect Corp
09/08/202322h05PR Newswire (US)DURECT Corporation Reports Second Quarter 2023 Financial Results and Business UpdateNASDAQ:DRRXDurect Corp
03/08/202322h30PR Newswire (US)DURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business UpdateNASDAQ:DRRXDurect Corp
21/07/202316h38Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:DRRXDurect Corp
20/07/202314h00PR Newswire (US)DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesNASDAQ:DRRXDurect Corp
23/06/202323h34Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:DRRXDurect Corp
 Showing the most relevant articles for your search:NASDAQ:DRRX

Dernières Valeurs Consultées

BOV
ESTR4F
ESTRELA PN
LSE
39VO
Res.mtg 17 A2bs
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés